Preplanned secondary analysis of the AZTEC trial in preterm infants: across 1108 respiratory aspirates from 348 infants, macrolide-resistance genes were similarly prevalent with azithromycin (63.9%) and placebo (63.7%); only erm(C) increased with azithromycin.
Secondary analysisn = 348
Aboklaish et al. Assessment of macrolide resistance in the respiratory tract of preterm-born infants during treatment with azithromycin in the AZTEC clinical trial